Nucleai Announces a Partnership with Sirona Dx for AI-Driven Discovery of Novel Spatial Biomarkers in Solid Tumors
Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, and Sirona Dx, a leading provider of multiomic single-cell analytical services, today announced a collaboration to advance the discovery of novel spatial biomarkers in solid tumors. The partnership combines Nucleai’s powerful AI spatial analytics platform with Sirona Dx’s […]
Nucleai Announces Partnership with Ultivue to Provide AI-Powered Spatial Biology Analysis to Complex Pathology Images
Nucleai, a leader in Artificial Intelligence (AI) powered spatial analysis for pathology, and Ultivue, an industry leader in multiplexing tools for tissue biomarker studies, today announced a collaboration to advance the discovery of novel spatial biomarkers. The partnership will layer Nucleai’s cutting-edge AI spatial models on top of Ultivue’s imaging technology to unlock the complex […]
Spatial biology is among the smaller segments of the broader life sciences market. One estimate issued in August by Research And Markets, has the market growing from 2021-2028 at a 10% compound annual growth rate $484.22 million, which would put its value this year at just under $250 million. The field made its way into the […]
Spatial biology company Nucleai has closed a $33 million Series B financing round led jointly by Section 32 and Sanofi Ventures, the firm announced on Tuesday. Nucleai plans to use the new financing to advance its spatial analysis platform and expand its commercial footprint across biopharmaceutical companies and contract research organizations. The company’s platform helps […]
Nucleai Closes $33 Million Series B Financing to Advance Spatial Biology Platform for Drug Research, Development and Diagnostics. Led by Section 32 and Sanofi Ventures, funding will enable Nucleai to expand its commercial footprint in biopharma and further develop its state-of-the-art spatial biology platform.